Valneva SE (NAS:VALN)
$ 4.3307 0.1342 (3.2%) Market Cap: 351.65 Mil Enterprise Value: 398.38 Mil PE Ratio: 0 PB Ratio: 1.60 GF Score: 69/100

Half Year 2021 Valneva SE Earnings Call Transcript

Aug 10, 2021 / 01:00PM GMT
Release Date Price: $26.66 (-11.13%)
Operator

Good day, and thank you for standing by, and now Valneva presents its Half Year 2021 financial results call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your host today, CEO of Valneva Thomas Lingelbach. Please go ahead.

Thomas Lingelbach
Valneva SE - Chairman of the Management Board, President & CEO

Good day, everyone. Welcome to our report on H1 '21 financials and general business update. While the first half of 2021 has been marked by tremendous success on our R&D side of the business, we have nicely delivered against our key major R&D objectives, and of course, the most recent news flow, probably at this moment in time, the most important one is related to our chikungunya vaccine. We are very proud to be the first company in the world that has successfully delivered a Phase III for a chikungunya vaccine, which continues to be a significant unmet medical need.

We made excellent progress on our other clinical assets

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot